You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Esophageal Squamous Cell Carcinoma

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy Trial (neoadjuvant anti-PD-1 (Keytruda) plus chemo)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Neoadjuvant Chemoimmunotherapy
  • neoadjuvant anti-PD-1 (Keytruda) plus chemotherapy
  • (no location specified)
Feb 14, 2023

Esophageal Squamous Cell Carcinoma in Malawi

Completed
  • Esophageal Squamous Cell Carcinoma
    • Lilongwe, Malawi
    • +1 more
    Jan 5, 2023

    Neoadjuvent, PD-1 Inhibitor, Chemo Trial in Xi'an (Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin)

    Recruiting
    • Neoadjuvent
    • +3 more
    • Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
    • Xi'an, Shaanxi, China
    • +2 more
    Aug 17, 2023

    Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy Trial in Shanghai (Tislelizumab)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • +2 more
    • Shanghai, Shanghai, China
      Shanghai chest hospital
    Sep 24, 2023

    Esophageal Squamous Cell Carcinoma Trial (AK104)

    Not yet recruiting
    • Esophageal Squamous Cell Carcinoma
    • (no location specified)
    Oct 25, 2022

    Esophageal Squamous Cell Cancer Trial in Beijing (Toripalimab, Paclitaxel, Cisplatin)

    Recruiting
    • Esophageal Squamous Cell Cancer
    • Beijing, Beijing, China
      Beijing Cancer Hospital / Peking University Cancer Hospital
    Jan 30, 2023

    NLR and Its Association With Efficacy of Immunochemotherapy in

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • +2 more
      • Guangzhou, Guangdong, China
        Guangdong Provincial People's Hospital
      Nov 10, 2023

      Metastatic Esophageal Squamous Cell Carcinoma Trial in Shanghai (Radiotherapy)

      Recruiting
      • Metastatic Esophageal Squamous Cell Carcinoma
      • Radiotherapy
      • Shanghai, China
        Fudan University Shanghai cancer center
      Feb 27, 2023

      Esophageal Squamous Cell Carcinoma Trial in Beijing (Fruquintinib in Combination with S-1)

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • Fruquintinib in Combination with S-1
      • Beijing, China
        Peking Union Medical College Hospital
      Dec 2, 2022

      Peripheral Blood Neoantigen Specific T Cells Predict Efficacy of

      Recruiting
      • Esophageal Squamous Cell Carcinoma
        • Shanghai, Shanghai, China
          Cancer hospital Fudan University
        Nov 30, 2022

        Esophageal Squamous Cell Carcinoma Trial in Xi'an (Tislelizumab + cisplatin + paclitaxel, Tislelizumab + radiotherapy)

        Enrolling by invitation
        • Esophageal Squamous Cell Carcinoma
        • Tislelizumab + cisplatin + paclitaxel
        • Tislelizumab + radiotherapy
        • Xi'an, Shaanxi, China
          The First Affiliated Hospital of Xi'an Jiaotong University
        Dec 21, 2022

        Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy Trial in Hangzhou (Serplulimab, Albumin paclitaxel, carboplatin AUC=5,

        Recruiting
        • Esophageal Squamous Cell Carcinoma
        • Neoadjuvant Therapy
        • Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy
        • Esophagectomy
        • Hangzhou, China
          2nd Affiliated Hospital, School of Medicine, Zhejiang University
        Dec 20, 2022

        Esophageal Squamous Cell Carcinoma Trial (Envafolimab, Albumin-Bound Paclitaxel, Carboplatin)

        Not yet recruiting
        • Esophageal Squamous Cell Carcinoma
        • (no location specified)
        Sep 21, 2022

        Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to

        Active, not recruiting
        • Esophageal Cancer
        • follow up
        • Guangzhou, Guangdong, China
          Jianhua Fu
        Sep 24, 2023

        Esophageal Squamous Cell Carcinoma Trial in Beijing (Pembrolizumab, Sinoporphyrin Sodium, Photodynamic therapy)

        Not yet recruiting
        • Esophageal Squamous Cell Carcinoma
        • Beijing, Beijing, China
          Beijing Cancer Hospital & Institute
        Nov 23, 2022

        Esophageal Squamous Cell Carcinoma, Chemo Effect, Side Effect of Drug Trial in Nanjing (Consolidation chemo (4 courses),

        Recruiting
        • Esophageal Squamous Cell Carcinoma
        • +2 more
        • Consolidation chemotherapy (4 courses)
        • Concurrent chemotherapy (2 courses)
        • Nanjing, Jiangsu, China
          The First Affiliated Hospital of Nanjing Medical University
        Mar 16, 2023

        Esophageal Squamous Cell Carcinoma Trial in Guangzhou (Moderately hypofractionated conformal radiation combined With S-1)

        Completed
        • Esophageal Squamous Cell Carcinoma
        • Moderately hypofractionated conformal radiation combined With S-1
        • Guangzhou, Guangdong, China
          Hui Liu
        Oct 25, 2022

        Esophagus Cancer Trial in Tianjin (Camrelizumab, Paclitaxel, Cisplatin)

        Recruiting
        • Esophagus Cancer
        • Tianjin, Tianjin, China
          Affiliated Cancer Hospital of Tianjin Medical University
        Nov 24, 2022

        Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Guangzhou (PD-1 combined with SBRT)

        Recruiting
        • Esophageal Squamous Cell Carcinoma
        • Oligometastatic Disease
        • PD-1 combined with SBRT
        • Guangzhou, Guangdong, China
          Mian Xi
        Dec 18, 2022

        Esophagus Cancer Trial in Guangzhou (Cadonilimab, Paclitaxel and cisplatin, intensity-modulated radiotherapy)

        Not yet recruiting
        • Esophagus Cancer
        • Guangzhou, Guangdong, China
          Sun Yat-sen University
        Nov 20, 2023

        Esophageal Squamous Cell Carcinoma Trial in Guangzhou (Toripalimab, Paclitaxel-albumin, Nedaplatin)

        Recruiting
        • Esophageal Squamous Cell Carcinoma
        • Guangzhou, Guangdong, China
          Sun yat-sen University Cancer Center
        Oct 25, 2022

        PFS Trial (Decitabine Injection, tirelizumab)

        Not yet recruiting
        • PFS
        • (no location specified)
        Nov 24, 2022

        Esophageal Squamous Cell Carcinoma Trial in Guangzhou (Split-course hypo-CCRT, Induction chemo-immunotherapy, Concurrent chemo)

        Recruiting
        • Esophageal Squamous Cell Carcinoma
        • Split-course hypo-CCRT
        • +2 more
        • Guangzhou, Guangdong, China
          Sun yat-sen University Cancer Center
        Aug 26, 2023

        Esophageal Carcinoma Trial (Immune Checkpoint Inhibitors)

        Not yet recruiting
        • Esophageal Carcinoma
        • Immune Checkpoint Inhibitors
        • (no location specified)
        Jul 6, 2023

        Identification of Breath Biomarkers in Esophageal Cancer

        Recruiting
        • Esophageal Squamous Cell Carcinoma
        • Breathing test
        • Guangzhou, Guangdong, China
          Mian Xi
        Oct 27, 2022